Get the latest news and updates
Under Steve's leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX® breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in discovery research and medical affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin®. In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. In 2017, Steve was recognized for his contributions to precision medicine and named one of the Top 100 Innovators in the country by PharmaVOICE.
New approaches are being adopted to overcome the challenges associated with matching and enrolling patients to the most appropriate clinical trial. Identifying opportunities for patients requires both an understanding of the patients’ molecular profile and other key clinical attributes to ensure enrollment data. In this session, we will learn about innovative and novel approaches and technologies that address clinical trial enrollment challenges.